The European Medicines Agency has recommended that a new artemisinin-based combination therapy be approved to treat malaria in adults, children and infants aged six months or older. The agent combines dihydroartemisinin and piperaquine. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
